Our transcriptome sequencing results showed that differentially expressed genes produced by FBXO22 silencing were significantly enriched in the HR pathway, indicating that overexpression of FBXO22 in lung cancer may induce radioresistance by activating the HR pathway. The gene discussed is FBXO22; the disease is lung carcinoma.